Related Experiment Video

Updated: Jul 22, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Advances in systemic therapy of small cell cancer of the lung

G A Daniels1, A A Adjei

  • 1Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.

Expert Review of Anticancer Therapy
|July 13, 2002
PubMed

Insights

Small cell lung cancer (SCLC) therapy has seen slow progress, but new treatments combining chemotherapy with novel agents offer hope. These advancements are improving survival rates for SCLC patients.

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Research

Background:

  • Small cell lung cancer (SCLC) therapy has shown limited progress over two decades.
  • Standard chemotherapy offers initial response but leads to rapid relapse, with a 5-year survival rate around 5%.

Purpose of the Study:

  • To review current SCLC treatment strategies.
  • To summarize recent clinical trials in SCLC therapy.
  • To provide an outlook on future SCLC treatment advancements.

Main Methods:

  • Literature review of recent clinical trials and treatment strategies for SCLC.
  • Analysis of data on survival rates and toxicity of novel therapeutic agents.
  • Synthesis of information to project future treatment directions.

Main Results:

  • Recent clinical trials combining standard regimens with newer agents have shown promise.
  • Combination therapies have, in some instances, doubled median survival for SCLC patients.
  • Novel targeted agents demonstrate potential for significantly increased survival with manageable toxicity.

Conclusions:

  • Emerging treatment strategies, including targeted agents, offer renewed hope for improving SCLC patient survival.
  • The combination of existing and novel therapies is key to overcoming SCLC's historical treatment challenges.
  • Future SCLC treatment is expected to involve more personalized and effective therapeutic approaches.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...